Abstract
The Food and Drug Administration (FDA) does not, as yet, have specific guidances for products containing nanoscale materials. As announced in the report issued by the FDA Nanotechnology Task Force (July 2007), however, there are recommendations to various centers within the FDA to develop guidances for industry. Regardless of the lack of explicit FDA guidances, there are therapeutics currently on the market containing nanoscale materials, and additional novel nanomaterial-containing therapeutics are being developed with the hopes of being submitted for regulatory review and approval. While, for the most part, these novel nanomaterial-containing products are being evaluated using the same regulatory requirements as products that do not contain nanomaterials, it is increasingly evident that at least in the area of characterization of nanomaterials used in drug products, there may be areas where special focus is needed. Specific areas include the validity of applying small molecule principles and methodologies to nanomaterial-containing products, the effects the nanomaterial will impart to the rest of the formulation (or vice versa), and how the physicochemical properties may be impacted by biological settings. Similarly, for safety evaluation, biodistribution studies will be at the core of any evaluation of products containing nanomaterials. These biodistribution studies will, in effect, be indicative of where the nanoparticles are traveling and possibly accumulating, therefore subjecting those sites to increased likelihood of toxicological effects. This chapter focuses on questions and considerations that may arise for sponsors during product characterization, as well as considerations for the appropriate design and conduct of in vivo toxicology studies. This chapter will also review how current FDA guidances apply to nanotherapeutics.
This chapter reflects the current thinking and experience of the authors. However, this is not a policy document and should not be used in lieu of regulations, published FDA guidances, or direct discussions with the agency.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Siegel, R.W., Hu, E., Roco, M.C. (eds.) (1999) Nanostructure Science and Technology. A Worldwide Study. National Science and Technology Council Committee on Technology, The Interagency working group on nanoscience, engineering and technology. International Technology Research Institute World Technology Division, Baltimore, MD.
Vogel, V., Baird, B. (eds.) (2003) Nanobio technology. Report of the National Nano technology Initiative Workshop. National Nanotechnology Initiative, Arlington, VA.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. Guidance for Industry Content and format of investigational new drug applications for phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products. 1995 http://www.fda.gov/cder/guidance/phase1.pdf accessed February, 2008.
Warheit, D. (2008) How meaningful are results of nanotoxicity studies in the absence of adequate material characterization? Toxicol Sci 101, 183–185.
Oberdorster, G., Oberdorster, E., Oberdorster, J. (2005) Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113, 823–839.
Gaur, U., Sahoo, S., De, T., Ghosh, P., Maitra, A., Ghosh, P. (2000) Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 202, 1–10.
Liversidge, G., Cundy, K. (1995) Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 125, 91–97.
Hu, J., Johnston, K., Williams, R. (2004) Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm 30, 233–245.
LaVan, D., McGuire, T., Langer, R. (2003) Small-scale systems for in vivo drug delivery. Nat Biotechnol 21, 1184–1191.
Nishiyama, N., Kataoka, K. (2006) Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 112, 630–648.
Hezinger, A., Tebmar, J., Gopferich, A. (2008) Polymer coating of quantum dots – a powerful tool toward diagnostics and sensorics. Eur J Pharm Biopharm 68, 138–152.
Dobson, J. (2006) Magnetic nanoparticles for drug delivery. Drug Dev Res 67, 55–60.
Castaldo, D. (2008) Identification of foreign particles below 10 microns key to inhaled drug quality. Pharmaceutical Processing. http://www.pharmpro.com/ShowPR.aspx?PUBCODE=021&ACCT=0000100&ISSUE=0405&RELTYPE=PR&Cat=0&SubCat=0&ProdCode=0000&PRODLETT=R&SearchText=aspex accessed April 1, 2008.
Adams, N., De Gans, B.-J., Kozodaev, D., Sanchez, C., Bastiaansen, C., Broer, D., Schubert, U. (2006) High-throughput screening and optimization of photoembossed relief structures. J Comb Chem 8, 184–191.
Draft Guidance Guidance for Industry, Analytical Procedures and Methods Validation, Chemistry, Manufacturing, and Controls Documentation, August 2000.
Magenheim, B., Benita, S. (1991) Nanoparticle characterization: A comprehensive physiochemical approach. STP Pharma Sci. 1, 221–241.
Bootz, A., Vogel, V., Schubert, D., Kreuter, J. (2004) Comparison of scanning electron microscopy, dynamic light scattering, and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 57, 369–375.
Jillavenkatesa, J., Dapkunas, S., Lum, L.-S. (2001) NIST recommended practice guide special publication 960-1 Particle size characterization. NIST.
Murdock, R., Braydich-Stolle, L., Schrand, A., Schlager, J., Hussain, S. (2008) Characteri zation of nanomaterial dispersion in solution prior to in vitro exposure using dynamic light scattering technique. Toxicol Sci 101, 239–253.
Guidance for Industry and FDA Staff, Early Development Considerations for Innovative Combination Products, September 2006 (http://www.fda.gov/oc/combination/innovative.html.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Tyner, K., Sadrieh, N. (2011). Considerations When Submitting Nanotherapeutics to FDA/CDER for Regulatory Review. In: McNeil, S. (eds) Characterization of Nanoparticles Intended for Drug Delivery. Methods in Molecular Biology, vol 697. Humana Press. https://doi.org/10.1007/978-1-60327-198-1_3
Download citation
DOI: https://doi.org/10.1007/978-1-60327-198-1_3
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-197-4
Online ISBN: 978-1-60327-198-1
eBook Packages: Springer Protocols